Iconix Signs Chemogenomics Agreement with Taisho | GenomeWeb

NEW YORK, June 15 (GenomeWeb News) - Iconix Pharmaceuticals will perform chemogenomics profiling and analysis services for Taisho Pharmaceutical of Japan, Mountain View, Calif.-based Iconix said today.

 

Under the agreement, Taisho will apply Iconix's DrugMatrix platform, a chemogenomics database, to help it select and optimize drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.